Stifel Nicolaus started coverage on shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) in a research report report published on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $20.00 price target on the stock.

A number of other research firms also recently commented on VYGR. BidaskClub raised shares of Voyager Therapeutics from a strong sell rating to a sell rating in a research note on Thursday, July 13th. TheStreet downgraded shares of Voyager Therapeutics from a c- rating to a d+ rating in a research note on Friday, April 21st. Zacks Investment Research downgraded shares of Voyager Therapeutics from a hold rating to a sell rating in a research note on Thursday, July 13th. Wedbush reaffirmed an outperform rating and set a $36.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, May 10th. Finally, ValuEngine downgraded shares of Voyager Therapeutics from a sell rating to a strong sell rating in a research note on Friday. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $25.33.

Voyager Therapeutics (NASDAQ:VYGR) opened at 8.24 on Friday. Voyager Therapeutics has a 52 week low of $8.22 and a 52 week high of $18.25. The firm’s 50-day moving average is $9.52 and its 200 day moving average is $10.79. The stock’s market cap is $221.26 million.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, May 9th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.11. Voyager Therapeutics had a negative net margin of 457.45% and a negative return on equity of 35.25%. The firm had revenue of $1.46 million during the quarter, compared to analyst estimates of $3.70 million. On average, equities research analysts expect that Voyager Therapeutics will post ($2.48) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/voyager-therapeutics-inc-nasdaqvygr-research-coverage-started-at-stifel-nicolaus/1465484.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in Voyager Therapeutics by 5.3% in the fourth quarter. State Street Corp now owns 165,503 shares of the company’s stock worth $2,108,000 after buying an additional 8,257 shares in the last quarter. Wellington Management Group LLP increased its position in Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after buying an additional 19,450 shares in the last quarter. Fiduciary Trust Co. increased its stake in Voyager Therapeutics by 19.1% in the first quarter. Fiduciary Trust Co. now owns 108,561 shares of the company’s stock worth $1,437,000 after buying an additional 17,386 shares during the period. Wells Fargo & Company MN increased its stake in Voyager Therapeutics by 114.4% in the first quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock worth $1,107,000 after buying an additional 44,599 shares during the period. Finally, Bessemer Group Inc. increased its stake in Voyager Therapeutics by 148.1% in the second quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock worth $402,000 after buying an additional 26,763 shares during the period. 41.24% of the stock is owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.